Takeda Pharmaceutical may sell Shire’s experimental inflammatory bowel disease drug to help clear European antitrust reviews and close its $62 billion takeover of Shire.
Takeda said that it has been in discussions with the European Commission about divesting Shire’s SHP647, which is in the final stages of experimental testing for the treatment of Crohn’s disease and ulcerative colitis.
Takeda is already marketing the drug Entyvio for those conditions.
European regulators have a Nov. 6 deadline to complete their review and the takeover already has the OK from China, the U.S. Federal Trade Commission, Brazil and Japan.
Read the Bloomberg coverage